Cargando…
Constitutive activation of p38 MAPK in tumor cells contributes to osteolytic bone lesions in multiple myeloma
Bone destruction is a hallmark of multiple myeloma and affects more than 80% of patients. However, current therapy is unable to completely cure and/or prevent bone lesions. Although it is accepted that myeloma cells mediate bone destruction by inhibition of osteoblasts and activation of osteoclasts,...
Autores principales: | Yang, Jing, He, Jin, Wang, Ji, Cao, Yabing, Ling, Jianhua, Qian, Jianfei, Lu, Yong, Li, Haiyan, Zheng, Yuhuan, Lan, Yongsheng, Hong, Sungyoul, Matthews, Jairo, Starbuck, Michael W, Navone, Nora M, Orlowski, Robert Z., Lin, Pei, Kwak, Larry W., Yi, Qing |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3381862/ https://www.ncbi.nlm.nih.gov/pubmed/22425892 http://dx.doi.org/10.1038/leu.2012.71 |
Ejemplares similares
-
Anti-β(2)-microglobulin monoclonal antibodies overcome bortezomib resistance in multiple myeloma by inhibiting autophagy
por: Zhang, Mingjun, et al.
Publicado: (2015) -
Osteosclerotic & osteolytic lesions in multiple myeloma
por: Ram, Rapur, et al.
Publicado: (2014) -
Sotatercept in patients with osteolytic lesions of multiple myeloma
por: Abdulkadyrov, Kudrat M, et al.
Publicado: (2014) -
Osteolytic lesions: Multiple myeloma or prostate cancer?
por: Devaraj, Akshitha, et al.
Publicado: (2023) -
Preventing osteolytic lesions and osteomyelitis in multiple myeloma
por: Dao, Aiken, et al.
Publicado: (2022)